Trials / Completed
CompletedNCT00654589
Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload
A One-year, Open-label, Single Arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/d) in Patients Three to Six Months After Allogeneic Hematopoietic Cell Transplantation in Whom Iron Overload is Present
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the effects of iron chelation using deferasirox in patients who show signs of iron overload after an allogeneic stem cell transplantation The iron overload must be due to blood transfusions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deferasirox |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2012-01-01
- Completion
- 2012-01-01
- First posted
- 2008-04-08
- Last updated
- 2016-11-17
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00654589. Inclusion in this directory is not an endorsement.